



Attorney Docket No. 70207-56,579

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peter C. Meltzer, et al.

U.S.S.N. 10/033,621

Art Unit: 1614

FILED: December 27, 2001

Examiner: Not Yet Assigned

FOR: TROPANE ANALOGS AND METHODS FOR INHIBITION OF
MONOAMINE TRANSPORT

RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, Postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on July 3, 2002.

By: Susan Miller

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)

Commissioner for Patents
Washington, D.C. 20231

Date July 3, 2002

Sir:

TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$_____ is required by 37 C.F.R. § 1.17(p).
or
- b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that


- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$_____ for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Date: July 3, 2002

Respectfully submitted,



Edward J. Adamson (Reg. No. 50,927)
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444



Sheet 1 of 1

RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.
70207-56,579SERIAL NO.
10/033,621

APPLICANT Peter C. Meltzer, et al.

FILING DATE:
12/27/2001ART UNIT:
1614

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
	AA	4,434,151	02/28/1984	Byrne, et al.			11/08/1982
	AB	4,673,562	06/16/1987	Davison, et al			08/19/1983
	AC	4,746,505	05/24/1988	Jones et al.			04/26/1985
	AD	5,426,189	06/20/1995	Kung et al.			05/24/1994
	AE	5,334,728	08/02/1994	Kung et al.			10/06/1992
	AF	5,122,361	06/16/1992	Kung et al.			04/17/1989
	AG	5,128,118	07/07/1992	Carroll et al.			08/09/1990
	AH	5,413,779	05/09/1995	Kuhar et al.			08/09/1991
	AI	5,439,666	08/08/1995	Neumeyer et al.			11/24/1994
	AJ	5,310,912	05/10/1994	Neumeyer et al.			02/25/1992
	AK	5,128,118	07/07/1992	Carroll et al.			08/09/1990
	AL	5,380,848	01/10/1995	Kuhar et al.			04/26/1994
	AM	5,980,860	11/09/1999	Kung et al.			07/16/1998
	AN	5,493,026	02/20/1996	Elmaleh et al.			10/25/1993
	AO	3,813,404	05/28/1974	Clark, et al.			11/15/1972
	AP	4,499,099	02/12/1985	Watts			06/09/1982
	AQ	6,350,758,B1	02/26/2002	Kozikowski, et al.			12/02/1997

TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

70207-56,579

SERIAL NO.

10/033,621


APPLICANT Peter C. Meltzer, et al.

FILING DATE:

12/27/2001

ART UNIT:

1614



UNITED STATES PATENT DOCUMENTS

RECEIVED

JUL 10 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	BA	WO 97/14445	04/24/1997	PCT			YES
	BB	WO 95/11901	05/04/1995	PCT			Yes
	BC	WO 93/09814	05/27/1993	PCT			Yes
	BD	EP 0 135 160 A2	03/27/1985	EPO			Yes
	BE	WO 98/24788	06/11/1998	PCT			Yes
	BF	GB 2349882 A	11/15/2000	PCT			Yes
	BG	WO 97/16210	05/09/1997	PCT			Yes
	BH	WO 97/47328	12/18/1997	PCT			Yes

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	Brandau, et al., Nucl. Med. Biol. (1994) Vol.21, No. 8, pp.1073-1081
CB	Bryson, et al., Inorg. Chem. (1988), 27, pp. 2154-2161
CC	Davison, et al., Inorg. Chem.(1981) Vol. 20, No. 6, pp. 1629-1632
CD	DiZio, et al., Bioconjugate Chemistry, (1991) Vol. 2, No. 5, pp.353-366
CE	DiZio, et al., Journal of Nuclear Medicine (1992) Vol. 33, No. 4, pp. 558-569
CF	Fritzberg, et al., J. Nucl. Med. (1981) Vol. 22, No.3, pp. 258-263
CG	Fritzberg, et al., J. Nucl. Med. (1982)Vol. 23, No. 7, pp. 592-598
CH	Gustavson, et al., NeoRx Corp, Seattle, WA 98119, pp. 5485-5488
CI	Hansen, et al., J. Nuc. Med. (1994) Vol, 35, No. 7, pp. 1198-1205
CJ	Jones, et al., J. Nucl. Med, (1982)Vol. 23, No. 9, pp. 801-809
CK	Steigman, et al., National Academy Press NAS-NS-3204 Prepared for the Committee on Nuclear and Radiochemistry, National Research Council (1992) pp.117-127

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT



TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

ATTY DOCKET NO.

70207-56,579

SERIAL NO.

10/033,621

APPLICANT Peter C. Meltzer, et al.

FILING DATE:

12/27/2001

ART UNIT:

1614

TECH CENTER 1600/2900

JUL 10 2002

RECEIVED

UNITED STATES PATENT DOCUMENTS

CL	Archer, et al., University of Essex, Colchester, England, pp.177-179
CM	Baldwin, et al., Yale Univ. School of Med., Westhaven, CT, pp. 329-332
CN	Kelly, et al., Amersham Int., Amersham, Bucks, UK, pp. 259-263
CO	Kung, et al., Univ. of PA, Philadelphia, PA, pp. 293-298
CP	Liu et al., The DuPont Merck Pharm. Co. N. Billerica, MA, pp. 383-393
CQ	Mahmood, et al., Harvard Medical School, Boston, MA, pp. 211-215
CR	Volkert, Univ. of Missouri Columbia, MO, pp. 17-26
CS	Davies, et al, <i>J. Med. Chem.</i> (1994) Vol. 37, No. 9, pp. 1262-1268
CT	Bennett, et al., <i>J. of Pharmacology</i> (1995) Vol. 272, No. 3, pp. 1176-1186
CU	Rao, et al, Eighth International Symposium on Radiopharmaceutical Chemistry, Princeton Univ. (1990) pp. 39-40
CV	Johannsen, et al., <i>Eleventh Intern. Symposium Radiopharmaceutical Chem. Abstracts</i> (1995), pp. 319-320
CW	Agoston, et al., <i>Amer. Chem. Society</i> , (1997) Vol. 40, No. 26, pp. 4329-4339
CX	Carroll, et al., <i>J. Med. Chem.</i> (1993) Vol. 36, No. 20, pp. 2886-2890
CY	Casy, et al., <i>J. Pharm. Pharmacol.</i> (1992) Vol. 44, pp. 787-790
CZ	Daum, et al., <i>J. Med. Chem</i> (1975), Vol. 18, No. 5, pp. 496-501
CAA	Holmquist, et al., <i>J. Med. Chem</i> (1996), Vol. 39, No. 21, pp. 4139-4141
CAB	Meegalla, et al., <i>J. Am. Chem. Soc.</i> (1995) Vol. 117, No. 44, pp. 11037-11038
CAC	Meegalla, et al., <i>J. Am. Chem. Soc.</i> (1996) Vol. 7, No. 4, pp. 421-429
CAD	Clarke, et al., <i>J. Med. Chem.</i> (1973) Vol. 16, No. 11, pp. 1260-1267
CAE	Ohmomo, et al., <i>J. Med. Chem.</i> (1992) Vol. 35, No. 1, pp. 157-162
CAF	Carroll, et al., <i>J. Med. Chem.</i> (1995) Vol. 38, No. 2, pp. 379-388
CAG	Kline, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 6, pp. 851-857
CAH	Meltzer, et al., <i>J. Med. Chem.</i> (1996) Vol. 39, No. 2, pp. 371-379
CAI	Meltzer, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 17, pp. 2661-2673

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT



TECH CENTER 1600/2900

JUL 11 2002

RECEIVED

ATTY DOCKET NO.

70207-56,579

SERIAL NO.

10/033,621

APPLICANT Peter C. Meltzer, et al.

FILING DATE:

12/27/2001

ART UNIT:

1614

TECH CENTER 1600/2900

JUL 10 2002

RECEIVED

UNITED STATES PATENT DOCUMENTS

CAJ	Meltzer, et al., <i>J. Med. Chem</i> (1994) Vol. 37, No. 13, pp. 2001-2010
CAK	Newman, et al., <i>J. Med. Chem.</i> (1999) Vol. 42, No. 18, pp. 3502-3509
CAL	Newman, et al., <i>J. Med. Chem.</i> (1995) Vol. 38, No. 20, pp. 3933-3940
CAM	Newman, et al., <i>Current Medicinal Chem.</i> (1998) Vol. 5, No. 4, pp. 305-319
CAN	Newman, et al., <i>J. Med. Chem.</i> (1994) Vol. 37, No. 15, pp. 2258-2261
CAO	Riley et al., <i>J. Med. Chem.</i> (1979) pp. 1167-1171
CAP	Van Eeken, et al., <i>Arch. Int. Pharmacodyn</i> (Netherlands) (1966) Vol. 22, No. 10, Vol. 159, No. 1, pp. 240-249
CAQ	Cesati, et al., <i>J. Labelled Cpd. Radiopharm.</i> (1999) Vol. 42, Suppl. j, pp. S150-S152
CAR	Fang, et al., <i>J. Labelled Cpd. Radiopharm.</i> (1999) Vol 42, Suppl. i, pp. S336-S338
CAS	Hoepping, et al., <i>Universitat Marburg, Pachbereich Kemchemie</i> , (1997) pp. 33-36
CAT	Hoepping, et al., <i>Bioorganic & Medicinal Chem.</i> (1998) Vol. 6, pp. 1663-1672
CAU	Hoepping, et al., <i>Bioorganic & Medicinal Chem.</i> (1996) Vol. 6, No. 23, pp. 2871-2874
CAV	Hoepping, et al., <i>J. Med. Chem.</i> (1998) Vol 41, No. 23, pp. 4429-4432
CAW	Madras, et al., <i>Synapse</i> (1996) Vol. 22, pp. 239-246
CAX	Meegalla, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 1, pp. 9-17
CAY	Meltzer, et al., <i>J. Med. Chem.</i> (1997) Vol. 40, No. 12, pp. 1835-1844
CAZ	Meltzer, et al., <i>J. Med. Chem.</i> (1993) Vol. 36, No. 7 pp. 855-862
CBA	Meltzer, et al., <i>Med. Chem. Research</i> (1998) pp. 12-34
CBB	Meegalla, et al., <i>Bioconjugate Chem.</i> (1996) Vol. 7, No. 4, pp. 421-429
CBC	Fischman, et al., <i>J. Nuclear Med.</i> (1999) Vol. 40, No. 5 Supplement, p. 262P
CBD	Mozley, et al., <i>J. Nuclear Med.</i> (1995) Vol. 36, No. 5, p. 32P
CBE	Myers, et al., <i>J. Nuclear Med.</i> (1995) Vol. 36, No. 5, p. 124P



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.
70207-56,579

SERIAL NO.
10/033,621

APPLICANT Peter C. Meltzer, et al.

FILING DATE:
12/27/2001

ART UNIT:
1614

UNITED STATES PATENT DOCUMENTS

Examiner:

Date:

RECEIVED
JUL 10 2002
TECH CENTER 1600/2900

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900